DRD2 and psychiatric disorder: DRD2 is the target of anti-psychotic medications and consistently appears as a significant locus across GWAS for psychiatric disorders and symptoms, including major depression (Meng et al., 2024), depressive symptoms (Nagel et al., 2018), anhedonia (Ward et al., 2019), suicide (Kimbrel et al., 2022), and addiction (Kimbrel et al., 2022).